Assembly Biosciences Files 8-K with Corporate Updates
Ticker: ASMB · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1426800
| Field | Detail |
|---|---|
| Company | Assembly Biosciences, INC. (ASMB) |
| Form Type | 8-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, amendment, financials
Related Tickers: ASMB
TL;DR
ASMB filed an 8-K, expect corporate updates soon.
AI Summary
Assembly Biosciences, Inc. filed an 8-K on December 12, 2024, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhibits. The company, formerly known as Ventrus Biosciences Inc., is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This filing indicates potential changes in the company's governance or financial structure, which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant negative news.
Key Numbers
- 001-35005 — SEC File Number (Identifies the company's filing with the SEC)
- 20-8729264 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Registrant
- Ventrus Biosciences Inc. (company) — Former company name
- December 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Principal executive offices
FAQ
What specific amendments were made to Assembly Biosciences' Articles of Incorporation or Bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary text.
What financial statements and exhibits are being filed with this 8-K?
The filing states that financial statements and exhibits are being filed, but their specific content is not detailed in the provided text.
When did Assembly Biosciences change its name from Ventrus Biosciences Inc.?
Assembly Biosciences, Inc. changed its name from Ventrus Biosciences Inc. on February 11, 2008.
What is the principal business address of Assembly Biosciences, Inc.?
The principal executive offices are located at Two Tower Place, 7th Floor, South San Francisco, California 94080.
What is the fiscal year end for Assembly Biosciences, Inc.?
The fiscal year end for Assembly Biosciences, Inc. is December 31.
Filing Stats: 863 words · 3 min read · ~3 pages · Grade level 13.7 · Accepted 2024-12-13 16:05:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 ASMB The Nasdaq Global Select Marke
Filing Documents
- asmb-20241212.htm (8-K) — 53KB
- asmb-ex3_1.htm (EX-3.1) — 296KB
- 0000950170-24-136183.txt ( ) — 530KB
- asmb-20241212.xsd (EX-101.SCH) — 31KB
- asmb-20241212_htm.xml (XML) — 5KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 12, 2024, the Board of Directors (the "Board") of Assembly Biosciences, Inc. (the "Company") approved an amendment and restatement of the Company's Amended and Restated Bylaws (the "Amended Bylaws"), effective as of such date. Among other updates, the Amended Bylaws: Update and expand the procedural and informational requirements for director nominations and other proposals submitted by stockholders under the Company's "advance notice" bylaws, including requiring additional background information and disclosures regarding proposing stockholders, proposed nominees and proposed items of business. Revise the deadline for advance notice of director nominations and other proposals submitted by stockholders for an annual meeting of the Company's stockholders to be generally not earlier than one hundred twenty (120) days and not later than ninety (90) days prior to the first anniversary of the preceding year's annual meeting. Require a stockholder soliciting proxies from other stockholders to use a proxy card color other than white, which is reserved for the exclusive use for solicitation by the Company or the Board. Provide that for a person to be eligible to be a nominee for election as a director, that person must deliver to the Company's Secretary (1) a completed and signed written questionnaire regarding his or her background and qualifications and (2) certain written representations and agreements related to his or her service on the Board enumerated in the Amended Bylaws. Require stockholders providing notice pursuant to the advance notice and "proxy access" provisions to further update and supplement the notice to ensure that the information provided in connection with the notice is true and correct as of the record date for the applicable annual meeting. Provide that a special meeting requested by stockholders need not be called if a similar item is includ
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 3.1 Amended and Restated Bylaws of Assembly Biosciences, Inc., effective December 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: December 13, 2024 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 2